Kornimate/medical-research-clean huggingface dataset:
dna repair and genetic susceptibility to lung cancer

Conditions: Lung Cancer; Single Primary Lung Cancer; Second Primary Lung Cancer

Summary: the purpose of this study is to help us better understand the cellular changes that may lead to the development of lung cancer. we want to compare people with a second primary lung cancer with those who have only a first primary lung cancer. we hope to use the information obtained in this study as the basis for future studies and will not regard the results from this study as final. we will analyze your blood cells and dna to measure the changes in several genes that we believe may be involved in lung cancer. we also want to evaluate the capacity for your dna to repair itself.


Eligibility criteria:
inclusion criteria: * cases will be eligible for inclusion if: * they have been diagnosed with a second primary lung cancer, and * they speak english or a language for which we have a translated consent form, and * they understand and agree to sign informed consent, and * they agree to give us a blood sample, and * they agree to give us a tissue sample when part of normal clinical procedures, and * they agree to complete the study questionnaires, and * they agree to have their pathology information reviewed. this could include biopsy specimens. controls will be eligible for inclusion if * they have been diagnosed with a first primary lung cancer, and * they speak english or a language for which we have a translated consent form, and * they understand and agree to sign informed consent, and * they agree to give us a blood sample, and * they agree to give us a tissue sample when part of normal clinical procedures, and * they agree to complete the study questionnaires, * they agree to have their pathology information reviewed. this will could include biopsy specimens. exclusion criteria: * subjects who do not meet the inclusion criteria as either cases or controls will not be eligible for this study. * control subjects who have a history of another cancer, other than nonmelanoma skin cancer or a first primary lung cancer, will not be eligible for this study. * control subjects who otherwise meet the eligibility requirements above but who have had chemotherapy and/or are currently being treated with chemotherapy will be excluded from the functional assay, but not from the genotyping.
text message intervention to improve adherence in adolescents and young adults with celiac disease

Conditions: Celiac Disease

Summary: this is a prospective randomized controlled trial investigating the impact of educational bidirectional text message reminders on gluten free diet adherence among adolescents and young adults with celiac disease age 12-24. participants will complete a series of online questionnaires assessing quality of life, patient activation, celiac symptoms, and self reported dietary adherence at the beginning and end of the study. participants will also have their blood drawn to measure tissue transglutaminase iga (ttg iga) antibody and deamidated gliadin peptide iga (dgp iga) at the beginning and end of the study. lab draws can be done locally, and are at no cost to the participant. patients are randomized to the intervention or control group based on enrollment ttg iga. intervention group receives 45 unique text messages over the 3 month study. a gift card is provided for participation in the study.


Eligibility criteria:
inclusion criteria: * age 12-24 * celiac disease diagnosed by a gastroenterologist at least 1 year prior to enrollment * participant with ability to read email and text messages in english * access to a mobile phone * unlimited text messaging plan or agreement to receive 45 text messages for the study exclusion criteria: * participant inability to answer survey questions and text prompts in english
frequency of episodes of hypoglycaemia during treatment with biphasic insulin aspart 30 in type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the aim of this trial is to investigate the difference in frequency of episodes of hypoglycaemia during treatment with biphasic insulin aspart 30 compared to biphasic human insulin 30 in subjects with well controlled type 2 diabetes.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * treated with insulin 1-3 injections daily for at least 6 months * body mass index (bmi) below 40 kg/m\^2 * hba1c (glycosylated haemoglobin a1c) below 9.5% at screening exclusion criteria: * total insulin dosage more than 1.8 iu/kg * impaired hepatic or renal function or significant cardiac problems
ready to use supplementary food in moderate childhood malnutrition

Conditions: Moderate Acute Malnutrition

Summary: since 2001, ready to use therapeutic foods (rutf) are widely used to treat severe malnutrition. their efficacy and effectiveness were proven in community therapeutic care programs. recently, the question rose if rutf would be more effective than enriched flours to treat moderate malnutrition. the purpose of this study is to compare the effectiveness of ready to use food supplementary-plumpy® and premix corn soy blend with oil in term of cure rate, weight gain, duration of treatment, morbidity and mortality in the treatment of moderate acute malnutrition. compare the longer term effect on nutritional status and morbidity (relapse?).


Eligibility criteria:
inclusion criteria: * all children aged 6 months to 5 years admitted to sfc outpatient care during the study period * whm between 70-79% (1977 nchs/who standard) without edema * approval from the caretaker exclusion criteria: * presence of the following signs: bilateral edema, muac\<110 mm , whm\< 70%(criteria for severe malnutrition), and medical complications necessitating hospitalisation * refusal to participate from caretaker

Keywords: moderate wasting malnutrition ready to use food fortified blended flour
respiratory training in friedreich's ataxia

Conditions: Friedreich Ataxia

Summary: this is a prospective interventional study of patients with friedreich's ataxia that receive respiratory strength training for a period of 12 weeks with two research visits at the beginning and at the end of the study period. visits include swallowing evaluation with fiberoptic endoscopic evaluation of swallowing, pulmonary function testing, surface electromyography and patient surveys.


Eligibility criteria:
inclusion criteria: * confirmed genetic testing of friedreich's ataxia * have an overall digest score of 1 or higher based on fees screening * are able to perform pulmonary function testing exclusion criteria: * have been on antibiotics within 15 days prior to baseline screening. * have been prescribed systemic corticosteroids or neuromuscular blocking agents within 15 days of the baseline screening * have an allergy or contraindication to topical lidocaine or oxymetazoline * have any other concurrent medical condition which, in the opinion of the investigators, would make the subject inappropriate to participate in testing or respiratory exercise
whole genome sequencing (chromoseq) as an adjunct to conventional genomic profiling in mds

Conditions: Whole Genome Sequencing; Myelodysplastic Syndromes

Summary: this is a single institution, prospective study of the whole genome sequencing assay, chromoseq. using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing chromoseq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (mds).


Eligibility criteria:
inclusion criteria patient: * diagnosis of mds, or a clinical suspicion for a new diagnosis of mds, for whom routine diagnostic testing is requested or planned to be requested. * seen in the outpatient setting. * not been previously treated with disease-modifying therapy (such as lenalidomide or hypomethylating agents). note: patients who have received transfusional support, erythropoietin-stimulating agents, growth factor support, or luspatercept are eligible. at least 18 years of age. -able to understand and willing to sign an irb approved written informed consent document. inclusion criteria physician: * treating physician at washington university school of medicine who directs therapy for individuals with hematologic malignancies. * able and willing to complete standardized questionnaires about stakeholder perceptions of chromoseq during the chromoseq implementation process. (written documentation of informed consent is not required.) exclusion criteria patient: -younger than 18 years of age exclusion criteria physician -does not treat patients at washington university school of medicine
a phase i study of ips cell generation from patients with copd

Conditions: Thoracic Diseases; Respiratory Tract Diseases; Cancer of Lung; Cancer of the Lung; Lung Cancer; Lung Diseases, Obstructive; COPD; Pulmonary Emphysema; Neoplasms, Lung; Neoplasms, Pulmonary; Pulmonary Cancer; Pulmonary Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell

Summary: as part of the long-term goal of successfully implementing tissue regeneration strategies in an individualized manner for patients with thoracic diseases including, but not limited to: cystic fibrosis, pulmonary fibrosis and pulmonary hypertension, the investigators will assess the feasibility of collecting skin biopsies from patients undergoing surgery for thoracic disease, culturing skin fibroblasts from the biopsy, and reprogramming these skin fibroblasts into induced pluripotent cells.


Eligibility criteria:
inclusion criteria: * undergoing thoracic surgery at the mayo clinic rochester * presence of a thoracic disease

Keywords: lung cancer thoracic chest pulmonary
erector spinae versus ilioinguinal/ ilio-hypogastric block in children undergoing inguinal surgeries

Conditions: Inguinal Hernia

Summary: investigators aim to compare the efﬁcacy of us-guided ii/ih nerve block versus us-guided es block for pediatric unilateral inguinal hernia repair with respect to postoperative analgesia

regarding patient registry; a prior g power analysis was done. 24 per group was determined to achieve 80% power to detect a difference of 60 min in time to first rescue analgesia between the two groups with a significance level (α) of 0.05 using a two-sided two-sample t-test; 25 patients were included per group to replace any dropouts. - statistical analysis: data will be analyzed through spss (statistical package for social sciences). program version 22. distribution of data will be first tested by the shapiro test. data will be presented as the mean and standard deviation (sd), median and range or numbers and percentages. for normally distributed data, the unpaired t-test will be used to compare the mean values of both groups. for pain score, mann whitney u test will be used. fisher's exact test will be used for comparison of categorical data. the p value ≤ 0.05 will be considered as the level of statistical significance.

Eligibility criteria:
inclusion criteria: * : american society of anesthesiologists physical status i - ii exclusion criteria: * history of clinically significant cardiac disease. * history of clinically significant hepatic disease. * history of clinically significant renal disease. * history of clinically significant neurological disease. * known allergy to local anaesthetics
diagnosis of structural heart disease using mcg

Conditions: Structural Heart Abnormality

Summary: the purpose of this prospective cohort study is to determine the parameters of cardiac magnetic imaging to identify structural heart disease using use transthoracic echocardiography or cardiac magnetic resonance as reference standard.


Eligibility criteria:
inclusion criteria: * those with suspected structural heart disease who are scheduled to undergo echocardiography or cardiac magnetic resonance. structural heart disease includes cardiomyopathy (hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, etc.), congenital heart disease (including ventricular septal defect, atrial septal defect, patent ductus arteriosus, tetralogy of fallot) syndrome, tricuspid valve malformation, etc.), valvular heart disease (aortic valve stenosis, mitral valve stenosis, etc.), ventricular remodeling caused by myocardial ischemia or cardiac structural changes. * signed the consent form. exclusion criteria: * those with atrial fibrillation, supraventricular tachycardia, atrioventricular block and other arrhythmias that have not returned to normal; * those who are thought to be incapable of completing the relevant examinations by an attending physicians (or physicians with higher qualifications) due to unstable clinical conditions, metal implants, etc., or those who are unable to perform the examinations; * those with obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply; * those with malignant tumors; * pregnant or lactating women.
immunogenicity of a trivalent influenza vaccine in chronic kidney disease patients undergoing hemodialysis

Conditions: Influenza; End Stage Renal Failure; Chronic Kidney Disease

Summary: during the 2013-2014 influenza season, ckd patients undergoing hd participated in the study. the patients were randomized into two groups (mf59-adjuvanted vaccine group or non-adjuvanted vaccine group) and were immunized with the respective vaccine. sera were collected prior to vaccination and at 1and 6 months post vaccination. levels of hemagglutination inhibition (hi) antibodies were measured.


Eligibility criteria:
inclusion criteria: * chronic kidney disease patients undergoing hemodialysis * who have given written informed consent at the time of enrollment exclusion criteria: * recipients of influenza vaccine of 2013-2014 season before the study * history of egg allergy

Keywords: influenza vaccines mf59 oil emulsion end stage renal failure on dialysis
circulating-water garment with forced-air warming and circulating-water mattress during abdominal surgery

Conditions: Hypothermia

Summary: the purpose of this study is to see if the combination of a circulating water mattress beneath the patient combined with forced air warming over top of the patient will prevent hypothermia (low body temperature) just as well as a garment that circulates warm water around the patient, during your major abdominal surgery. patients will be randomly assigned to one of these two groups.

group a: this group will receive the circulating water garment group b: this group will receive the circulating water mattress and be covered by a forced air warming device for both the upper body and lower body once the patient is moved to the operating room table, the surface of the back will begin to be warmed using either the circulating-water garment for those in group a or the circulating-water mattress for those in group b. following the start of anesthesia, additional warming will be done by covering the large parts of the legs and the upper and side of the chest using either the circulating-water garment for those in group a or upper- and lower-body forced-air warmers for those in group b. patient involvement will last until the warming devices are removed prior to departure from the operating room. there is no follow-up to this study.

Eligibility criteria:
inclusion criteria: * major abdominal surgery * age between 18 and 85 years. exclusion criteria: * fever (core temperature \>38°c) * combined procedures (e.g.: simultaneous liver and kidney transplantation) * contraindication to forced-air or circulating-water warming which would be impacted by use of warming blanket * anticipated veno-venous bypass * current pregnancy

Keywords: abdominal surgery hypothermia circulating water mattress
a first-in-human study looking at the safety of zp8396 and how it works in the body of healthy trial participants

Conditions: Overweight; Healthy Volunteers

Summary: the research study will investigate the safety and tolerability of zp8396 in healthy study participants. in addition, the study will investigate how zp8396 works in the body (pharmacokinetics and pharmacodynamics). participants will receive 1 single dose either as an injection under the skin (subcutaneous, s.c.) or an injection into a vein of one arm (intravenous, i.v.). participants will have 9 visits with the study team. one of these visits consists of 8 overnight stays at the study site. for each participant, the study will last up to 66 days.


Eligibility criteria:
inclusion criteria: * healthy male subject * body mass index (bmi) between 21.0 and 29.9 kg/m\^2, both inclusive * body weight of at least 70.0 kg * glycosylated hemoglobin a1c (hba1c) less than 5.7 percent * further inclusion criteria apply exclusion criteria: * history of metabolic diseases more frequently associated with obesity, e.g. type-2-diabetes mellitus, hypertension, dyslipidemia, heart disease or stroke * systolic blood pressure \ 139 mmhg and/or diastolic blood pressure less than 50 mmhg or greater than 89 mmhg * symptoms of arterial hypotension * further exclusion criteria apply
evaluation of the entresto effect on sympathic nervous system in patient with heart failure

Conditions: Heart Failure

Summary: the hyperactivation of the sympathetic nervous system is a feature of the heart failure and the determinants of disease progression and risk of sudden cardiac death. this research project aims to study, in the drug use conditions provided in the summary of product characteristics based on european marketing authorization (indications and dosage), the effect of the entresto® on the activity of sympathic nervous system using the reference method, the microneurographic recording of sympathetic activity in muscle destiny (msna). this study will try to determine if the double inhibition of at1 receptor and neprilysin activity result in lower sympathic nervous system burst rate versus single at1 receptor inhibition using angiotensin-converting-enzyme inhibitor or at1 receptor of angiotensin ii inhibitor.


Eligibility criteria:
inclusion criteria: * men or women with heart failure with symptomatic left ventricular systolic dysfunction (left ventricular ejection fraction ≤ 40 %) with : * functional class new york heart association ii and at least 2 hospitalizations for cardiac decompensation in the year with n terminal pro brain-type natriuretic peptide ≥300 pg/ml (or brain-type natriuretic peptide ≥100 pg/ml) or usage of intravenous diuretics, * functional class new york heart association iii-iv, * insufficiently controlled by alternative drug-free therapies (surgery, cardiac resynchronization ...) or well managed drug therapies: angiotensin-converting-enzyme inhibitor, at1 receptor of angiotensin ii inhibitor diuretics or beta blockers. * treated by maximum dosage of at1 receptor of angiotensin ii inhibitor or angiotensin-converting-enzyme inhibitor for new york heart association ii patient or 50% of the recommended dose for new york heart association iii-iv patients or new york heart association ii patients with clinical manifestation restricting the use of maximum dosage, like orthostatic hypotension. * patient member of his home social security scheme exclusion criteria: * patient who are receiving direct renin inhibitor like aliskiren * patient who are receiving phosphodiesterase v inhibitors * patient who are receiving a potassium-sparing drug * patient with medical history of angioedema with previous treatment by angiotensin-converting-enzyme inhibitor or at1 receptor of angiotensin ii inhibitor * hypersensitivity to any component of entresto® * adult protected by the law * severe renal impairment (dfge \<30 ml/min/1,73 m2) * severe hepatic impairment, cirrhosis or cholestasis (child-pugh c class) * patient with are receiving anticoagulant therapies or suffering from known hemostatic trouble * patient participating in another biomedical research or with an active exclusion period * pregnancy * breast-feeding

Keywords: nervous system cardiac disease
suprachoroidal injection of cls-ta in subjects with macular edema associated with non-infectious uveitis

Conditions: Uveitis; Uveitis, Posterior; Uveitis, Anterior; Uveitis, Intermediate; Panuveitis

Summary: the study is designed to evaluate the safety and efficacy of suprachoroidally administered triamcinolone acetonide, cls-ta, in subjects with macular edema associated with non-infectious uveitis.

this is a phase 3, randomized, masked, sham-controlled, multicenter study to assess the safety and efficacy of 4 mg of cls-ta administered via suprachoroidal injection compared to a sham injection procedure in the treatment of subjects with macular edema associated with non-infectious uveitis. qualified subjects will be randomized to receive two suprachoroidal injections of cls-ta administered to the study eye or two sham injection procedures administered to the study eye approximately 12 weeks apart (visit 2 and visit 5). follow-up visits will be conducted monthly up to 24 weeks (visit 8).

Eligibility criteria:
inclusion criteria: * diagnosis of non-infectious uveitis (pan, anterior, intermediate and posterior) * diagnosis of macular edema associated with non-infectious uveitis (retinal thickness ≥ 300 microns) * visual acuity score of ≥ 5 letters read (20/800 snellen equivalent) and ≤ 70 letters read (20/40 snellen equivalent), in the study eye exclusion criteria: * any active ocular disease or infection in the study eye other than uveitis * intraocular pressure \> 22 mmhg or uncontrolled glaucoma in the study eye; subjects are not excluded if iop ≤ 22 mmhg with no more than 2 iop lowering medications. * any uncontrolled systemic disease that, in the opinion of the investigator, would preclude participation in the study * any topical ocular corticosteroid in the 10 days prior to baseline; intraocular or periocular corticosteroid injections in the 2 months prior to baseline; an ozurdex implant in the 6 months prior to baseline; retisert or iluvien implant in the 3 years prior to baseline.

Keywords: uveitis ume posterior uveitis anterior uveitis intermediate uveitis panuveitis non-infectious uveitis triamcinolone choroid choroidal injection suprachoroidal microneedle microinjection triamcinolone acetonide